Oncology biomarkers market seen hitting $33.63 billion by 2030

The oncology biomarkers market is projected to grow from $19.73 billion in 2026 to $33.63 billion by 2030, driven by personalized cancer treatment, liquid biopsy adoption and AI-led discovery. North America held the largest share in 2025 as cancer incidence and screening demand continue to rise.

Why it matters: - Oncology biomarkers help diagnose cancer, predict treatment response and track disease progression or relapse. - The market is expanding as cancer care shifts toward personalized medicine, earlier detection and ongoing monitoring. - Faster biomarker adoption could improve treatment selection and patient outcomes across oncology.

What happened: - The Business Research Company released a report on the global oncology biomarkers market covering 2026 to 2035. - The market is projected to grow from $17.3 billion in 2025 to $19.73 billion in 2026, a 14.1% CAGR. - The report forecasts the market will reach $33.63 billion by 2030, growing at a 14.3% CAGR. - North America held the largest market share in 2025.

The details: - Historical growth has been supported by cancer screening programs, molecular biology research, wider access to biomarker testing platforms, more oncology clinical trials and stronger collaboration between research institutions and hospitals. - Future growth is expected to come from demand for personalized oncology treatments, AI-driven biomarker discovery, investment in cancer genomics, broader use of liquid biopsy and a sharper focus on early detection and patient monitoring. - Trends expected to shape the market include precision oncology diagnostics, more use of genetic and protein biomarkers, bioinformatics integration, companion diagnostic development and tailored cancer therapies. - Oncology biomarkers include genes, proteins and other molecules that reveal the presence or progression of cancer. - The report says biomarkers help clinicians design more personalized treatment plans. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising global cancer incidence is the clearest demand driver. - The World Health Organization projected in February 2024 that by 2050 there will be more than 35 million new cancer cases worldwide, up 77% from about 20 million in 2022. - That outlook increases pressure on health systems to use biomarkers for faster diagnosis and more targeted treatment. - North America’s lead suggests the region has the deepest adoption of biomarker testing and related oncology infrastructure.

What's next: - Market growth is likely to continue as liquid biopsy, bioinformatics and companion diagnostics move further into routine oncology workflows. - The report points to sustained demand for tools that support earlier detection and continuous patient monitoring. - The Business Research Company is also offering expert contacts and social channels for follow-up on the report.

The bottom line: - Oncology biomarkers are moving from a specialized tool to a core part of cancer care, and the market is on track for strong double-digit growth through 2030.